BRIEF-Coherus Biosciences announces positive topline 24-week treatment Phase 3 results for CHS-1420 in patients with Psoriasis
January 10, 2017 at 09:22 AM EST
* Coherus Biosciences announces positive topline 24-week treatment phase three results for CHS-1420 (HUMIRA biosimilar candidate) in patients with Psoriasis